Investigational New Drugs高引用文章

• Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience

  引用次数：28

• Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads

  引用次数：28

• Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma

  引用次数：23

• Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis

  引用次数：22

• Radiomics to predict immunotherapy-induced pneumonitis: proof of concept

  引用次数：19

• Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors

  引用次数：18

• Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma

  引用次数：18

• Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment

  引用次数：15

• Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma

  引用次数：14

• Lopinavir-NO, a nitric oxide-releasing HIV protease inhibitor, suppresses the growth of melanoma cells in vitro and in vivo

  引用次数：13